MENLO PARK, Calif.--(BUSINESS WIRE)--The Penfold Patterson Research Institute (http://www.ppriworldhealth.org/) announced today that it will embark on two pivotal diagnostic trials of early-stage breast cancer detection with MD Anderson Cancer Center in Houston, Texas. The first study will be focused on the simultaneous detection of protein, mRNA, and DNA content in cells using multi-parametric cytometry (IncellDx OncoBreast3Dx®) and bioinformatics on fine needle aspirate samples (FNA) to determine the presence or absence of malignancy. The second study will use an alternative set of proprietary algorithms derived using OncoBreast3Dx®and bioinformatics to determine whether metastasis to regional lymph nodes has occurred.
Carol Penfold-Patterson, Executive Director of the Institute, said “We are excited and pleased to collaborate with MD Anderson in this critically important work. An early-stage prognostic screen for breast cancer malignancy will complement our current efforts underway in India and South Africa with flow cytometry-based HPV mRNA screening for cervical cancer.” PPRI is a non-profit institute devoted to delivering low-cost diagnostics to the developing world.
Enrollment for the studies will be begin in early Q2, 2015.
About PPRI: PPRI’s mission is to deliver state-of-the-art, low-cost diagnostics for breast and cervical cancer screening in underserved areas of the world, utilizing existing medical diagnostic instruments.
About IncellDx: IncellDx is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, HIV/AIDS, hepatitis and organ transplant rejection. The company is built around its patented technology for simultaneous, multiplex detection of protein, mRNA, and DNA biomarkers in single cells using flow cytometry. The company is privately held and located in Menlo Park, California.